We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Discovered by BeiGene researchers, pamiparib inhibits both PARP1 and PARP2. It is being developed as a monotherapy and combination therapy for various solid tumours.